Case series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma

Cheong Ngai, Shaji Kumar, Garrett Chi-lai Ho, Sirong Chen, Chor Sang Chim

Research output: Contribution to journalArticlepeer-review

Abstract

Complete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-avid. On the other hand, 11C-Acetate (ACT) has been found to be a more sensitive and specific tracer than FDG in MM. Recently, the addition of daratumumab to bortezomib, thalidomide, dexamethasone (VTd) or bortezomib, lenalidomide, dexamethasone (VRd) backbone has been proven to improve outcomes. Herein, we report three newly-diagnosed MM patients achieving deep responses with imaging CR using ACT PET in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based quadruplet induction regimen.

Original languageEnglish (US)
JournalTherapeutic Advances in Hematology
Volume12
DOIs
StatePublished - 2021

Keywords

  • 3-weekly daratumumab
  • C-Acetate PET
  • MRD negativity
  • newly diagnosed multiple myeloma
  • quadruplet induction

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Case series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this